{"preliminary_commentary":{"by_channel":{"x_thread":18,"youtube":4,"podcast":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03090659\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"LEGEND-2","nct_id":"NCT03090659","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=legend-2-nct03090659. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"LEGEND-2","arms":[{"description":"r/r multiple myeloma patients be treated with a split doses of LCAR-B38M cells. Total dose of 0.5-5 millions /kg cells will be administered at day 0, day 2 and day 6 by split dose (20%, 30% and 50% respectively).","label":"LCAR-B38M treatment group","type":"EXPERIMENTAL"}],"collaborators":["Second Affiliated Hospital of Xi'an Jiaotong University","Ruijin Hospital","Jiangsu Provincial People's Hospital","Shanghai Changzheng Hospital"],"completion_date":{"date":"2023-12-31","type":"ESTIMATED"},"conditions":["Refractory or Relapsed Multiple Myeloma"],"enrollment":{"count":100,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"LCAR-B38M CAR-T cell injection","otherNames":[],"type":"BIOLOGICAL"}],"last_update":"2023-06-12","lead_sponsor":"Nanjing Legend Biotech Co.","official_title":"A Clinical Study of Legend Biotech BCMA-chimeric Antigen Receptor Technology in Treating Relapsed/Refractory (R/R) Multiple Myeloma Patients","overall_status":"UNKNOWN","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2023-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Occurrence of treatment related adverse events as assessed by CTCAE v4.0","timeFrame":"Day 1-30 days after injection"}],"references":[{"citation":"Xu J, Wang BY, Yu SH, Chen SJ, Yang SS, Liu R, Chen LJ, Hou J, Chen Z, Zhao WH, He AL, Mi JQ, Chen SJ. Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial. J Hematol Oncol. 2024 Apr 24;17(1):23. doi: 10.1186/s13045-024-01530-z.","pmid":"38659046","type":"DERIVED"},{"citation":"Palmer S, Lin Y, Martin TG, Jagannath S, Jakubowiak A, Usmani SZ, Buyukkaramikli N, Phelps H, Slowik R, Pan F, Valluri S, Pacaud L, Jackson G. Extrapolation of Survival Data Using a Bayesian Approach: A Case Study Leveraging External Data from Cilta-Cel Therapy in Multiple Myeloma. Oncol Ther. 2023 Sep;11(3):313-326. doi: 10.1007/s40487-023-00230-x. Epub 2023 Jun 4.","pmid":"37270762","type":"DERIVED"},{"citation":"Zhao WH, Wang BY, Chen LJ, Fu WJ, Xu J, Liu J, Jin SW, Chen YX, Cao XM, Yang Y, Zhang YL, Wang FX, Zhang PY, Lei B, Gu LF, Wang JL, Zhang H, Bai J, Xu Y, Zhu H, Du J, Jiang H, Fan XH, Li JY, Hou J, Chen Z, Zhang WG, Mi JQ, Chen SJ, He AL. Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). J Hematol Oncol. 2022 Jul 6;15(1):86. doi: 10.1186/s13045-022-01301-8.","pmid":"35794616","type":"DERIVED"},{"citation":"Zhao WH, Liu J, Wang BY, Chen YX, Cao XM, Yang Y, Zhang YL, Wang FX, Zhang PY, Lei B, Gu LF, Wang JL, Yang N, Zhang R, Zhang H, Shen Y, Bai J, Xu Y, Wang XG, Zhang RL, Wei LL, Li ZF, Li ZZ, Geng Y, He Q, Zhuang QC, Fan XH, He AL, Zhang WG. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol. 2018 Dec 20;11(1):141. doi: 10.1186/s13045-018-0681-6.","pmid":"30572922","type":"DERIVED"}],"start_date":{"date":"2015-10-02","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT03090659"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/legend-2-nct03090659"}